Put companies on watchlist
aap Implantate AG
ISIN: DE000A3H2101
WKN: A3H210
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

aap Implantate AG · ISIN: DE000A3H2101 · EQS - adhoc news (94 News)
Country: Germany · Primary market: Germany · EQS NID: 1973467
22 August 2024 06:05PM

Auditor will terminate audit and declare non-issuance of audit opinion due to audit impediments


EQS-Ad-hoc: aap Implantate AG / Key word(s): Annual Report
aap Implantate AG: Auditor will terminate audit and declare non-issuance of audit opinion due to audit impediments

22-Aug-2024 / 18:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("Company") today received notification from the auditor, Baker Tilly GmbH & Co KG Wirtschaftsprüfungsgesellschaft ("Auditor"), that it will conclude the audit of the annual and consolidated financial statements on Friday, August 23, 2024, and will declare that it will not issue an audit opinion due to audit impediments. The auditor justifies this by stating that it is not in a position to complete the audit because, in its view, the necessary documents relating to the HGB individual financial statements have not been submitted in full.

The publication of the 2023 annual financial statements despite the fact that the audit has not been completed is therefore accompanied by a note of refusal. The decision to publish was made due to the threat of a six-figure penalty payment. The Executive Board is working with all available resources to resolve the audit impediment and eliminate it for the 2024 annual and consolidated financial statements.

aap Implants AG

Management Board

 

 

 

 





Contact:
aap Implantate AG; R. Di Girolamo; Vorsitzender des Vorstands / CEO; Lorenzweg 5; D-12099 Berlin
Tel.: +49/30/750 19 – 170; Fax: +49/30/750 19 – 290; r.digirolamo@aap.de


End of Inside Information

22-Aug-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 019-0
Fax: +49 (0) 30 75 019-111
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1973467

 
End of Announcement EQS News Service

1973467  22-Aug-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1973467&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - aap Implantate AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.